Integumen are licensed to sell wholesale volumes of human grade food supplements into the food sector, protein enriched food into the animal feed sector, bioplastic ingredients to the cosmetic industry. These are complementary to Integumen’s skincare, animal-free skin science testing and cosmetic businesses.
Country of Incorporation
Integumen plc is incorporated in England and Wales with Registration Number 10205396. Integumen plc has operations in Germany, Ireland, the UK and North America, and its main country of operation is the UK.
Sand Hutton Applied innovation Campus
Sand Hutton, York
North Yorkshire YO41 1LZ
19 Railway Road
Dalkey, Co. Dublin
Articles of Association
The Company’s Articles of Association can be downloaded here
Management and Board
Board of Directors
Anthony (“Tony”) Richardson, Non-Executive Chairman Tony is a Fellow of the Association of Chartered Certified Accountants. He co-founded Alltracel Pharmaceuticals Plc (“Alltracel”) in 1996. Alltracel was admitted to trading on AIM in 2001 and successfully made a number of acquisitions in the area of oral health before a trade sale in 2008 to Hemcon Medical Technologies Inc. Tony joined Venn Life Sciences in 2007 as non-executive Chairman. In 2010, he assumed the role of Chief Executive Officer and in that year Venn Life Sciences completed two acquisitions that provide the basis for the current business.
Gerard Brandon, Chief Executive Officer Gerard was appointed Director and CEO of Integumen in August 2018. Previously, he joined Cellulac Limited (Ireland) as its Chief Executive Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. In 1996 he became founder and CEO of Alltracel Pharmaceuticals PLC, where he built a team that oversaw numerous patents granted on refined cellulose. Alltracel was admitted to trading on AIM in 2001. In 2004, he was appointed as a Managing Partner for Farmabrand Private Equity. In 2009, he was appointed as an Executive Consultant to Eplixo Limited. He is a Fellow of the Ryan Academy of Entrepreneurs in Dublin.
Camillus Glover, Chief of Finance and Operations Camillus was appointed Director and COO of Integumen in August 2018. on the 29th of August he took over as Chief Financial Officer. Previously, he joined Cellulac Limited (Ireland) as Chief Financial Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. He is a member of the Institute of Chartered Accountants Ireland. In 2003, he joined Alltracel as Commercial Director and was appointed Chief Operations Officer in 2005 until it was acquired in 2008 by Hemcon Medical Technologies (“Hemcon”). Between 2009 and 2012, he was VP of Global Business Development for Hemcon prior to joining Cellulac.
Ross Andrews, Non-Executive Director Ross is a highly experienced corporate adviser with 30 years’ experience advising companies and management teams on public market transactions, largely in the UK but also in Europe, Australia, and Asia. He has worked with large corporates as well as numerous small, growing companies, providing advice on a range of equity capital matters, including I POs, fundraisings, strategy, acquisitions, corporate governance and shareholder matters. Ross was a director and shareholder of Zeus Capital Limited until July 2015 when he formed RMA Consultancy Limited to undertake non-executive appointments or consultancy and project management roles within companies undergoing management change, external investment rounds or seeking a liquidity event through IPO or other exits.
Securities in Issue
As at 7 August 2018, the number of securities in issue was 263,608,327
As at 7 August 2018, shareholders holding more than 3% of the share capital of Integumen were:
|Shareholder Name||No. of Ordinary Shares||% of Existing Share Capital|
|Venn Life Sciences||42,244,672||16.03%|
|Tony Richardson *1||2,840,414||1.08%|
|Donald Nicholson *2||-||-|
*2 Donald Nicholson is the sole shareholder of Mercuriali which is the majority shareholder in Enhance. Enhance owns Ordinary Shares in the Company
Shares not in public hands
As at 7 August 2018, 60.9% of the Company’s securities were not in public hands
Restrictions in transfer of securities
There are no restrictions on the transfer of Integumen’s securities
Other exchanges and trading platforms
Integumen plc has not applied or agreed to have its securities admitted or traded on any other exchanges or trading platforms
UK City Code on Takeovers and Mergers
Integumen plc is subject to the UK City Code on Takeovers and Mergers legislation
Page last updated 7 August 2018
Share Dealing Code
The Board has adopted a share dealing code consistent with Rule 21 of the AIM Rules for Companies and MAR to regulate dealings in the Ordinary Shares by Directors and any other applicable employees (as defined by the AIM Rules for Companies). The Directors consider that this share dealing code is appropriate for a company whose shares are admitted on AIM.
The Company will take proper steps to ensure compliance by the Directors and applicable employees with the terms of the share dealing code and the relevant provisions of the AIM Rules for Companies (including Rule 21).
Reports & Accounts
Integumen PLC Interim Report 2018 – download pdf version.
Integumen PLC Annual Report 2017 – download pdf version.
Integumen PLC Interim Report 2017 – download pdf version.
Integumen PLC Annual Report 2016 – download pdf version.
Circulars & Notices
Admission Document The Company’s Admission Document can be downloaded here.
Articles of Association
The Company’s Articles of Association can be downloaded here.
AIM Rule 26
AIM Rule 26
The following information is disclosed for the purposes of compliance with AIM Rule 26. This information was last updated on 5 April 2017.
Description of the business see Company Information
Names of the Directors and biographical details see Board of Directors
Responsibilities of the Directors see Corporate Governance
Country of incorporation/operation see Company Information
Current Constitutional documents see Company Documents
Shareholder Information see Shareholder Information
- Number of securities in issue
- Significant shareholders
- Shares not in public hands
- Restrictions on transfer of securities
- Other exchanges and trading platforms
- UK City Code on Takeovers and Mergers
Corporate governance code see Corporate Governance
Company announcements made in the past 12 months see Regulatory News Service (RNS)
Financial Information see Reports and Accounts
Admission document and circulars see Company Documents
Advisers see Advisers
|Spark Advisory Partners Limited|
5 St John's Lane
London EC1M 4BH
|Turner Pope Investments (TPI) Ltd
6th Floor, Becket House
36 Old Jewry,
London EC2R 8DD
20 Ironmonger Lane
London EC2V 8EP
Neville Registrars Limited
18 Laurel Lane
Halesowen B63 3DA
5 Chancery Lane
London EC4A 1BL
Jeffreys Henry LLP
Finsgate 5-7 Cranwood Street
London EC1V 9EE
|Solicitors to Integumen
BPE Solicitors LLP
St James House
St James Square
Cheltenham GL50 3PR
|Solicitors to the Nominated Advisor and Broker|
Addleshaw Goddard LLP
60 Chiswell Street
London EC1Y 4AG
Have an Investor Question?
Email us anytime
Or call — +44 (20) 3239 3716